Literature DB >> 31773704

MiR-155 inhibits proliferation, invasion and migration of melanoma via targeting CBL.

H Li1, J-B Song, H-X Chen, Q-Q Wang, L-X Meng, Y Li.   

Abstract

OBJECTIVE: Malignant melanoma (MM), the deadliest form of skin malignancy, is a highly aggressive and malignant tumor with an increasing incidence rate in recent years. Increasing evidence suggested that dysfunctions of microRNAs (miRNAs) may play an important role in human tumors. However, the effect of miR-155 on malignant melanoma cell migration and invasion remains largely elusive. This research was designed to evaluate the potential function of miR-155 and CBL (Casitas B-lineage lymphoma) in malignant melanoma. PATIENTS AND METHODS: Quantitative Real-time polymerase chain reaction (qRT-PCR) was utilized to detect miR-155 and CBL expression in malignant melanoma tissues and cell lines. 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2-H-tetrazolium bromide (MTT) assay was performed to examine the regulation of miR-155 in melanoma proliferation. Transwell assay was carried out to detect the effect of miR-155 on the MM cell migration and invasion. Luciferase assay and biological analysis were used to predict and determine the target gene of miR-155.
RESULTS: miR-155 was down-regulated in malignant melanoma tissues and cell lines. Ectopic expression of miR-155 could inhibit migration and invasion in malignant melanoma cells. What's more, we found that CBL was a new target of miR-155. Additionally, CBL was negatively associated with miR-155 in malignant melanoma and overexpression of CBL attenuated miR-155-mediated inhibition on MM cell migration and invasion.
CONCLUSIONS: miR-155 inhibited malignant melanoma proliferation, migration and invasion. And high CBL expression was observed in MM tissues. This newly identified miR-155/CBL axis may provide new insight into the pathogenesis of malignant melanoma.

Entities:  

Year:  2019        PMID: 31773704     DOI: 10.26355/eurrev_201911_19447

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  6 in total

1.  microRNA-155-5p initiates childhood acute lymphoblastic leukemia by regulating the IRF4/CDK6/CBL axis.

Authors:  Xiaojun Sun; Guotao Guan; Yunpeng Dai; Ping Zhao; Liying Liu; Qi Wang; Xiuli Li
Journal:  Lab Invest       Date:  2021-11-13       Impact factor: 5.662

Review 2.  MicroRNA Signature in Melanoma: Biomarkers and Therapeutic Targets.

Authors:  Soudeh Ghafouri-Fard; Mahdi Gholipour; Mohammad Taheri
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

Review 3.  miRNA as a Modulator of Immunotherapy and Immune Response in Melanoma.

Authors:  Mai-Huong Thi Nguyen; Yueh-Hsia Luo; An-Lun Li; Jen-Chieh Tsai; Kun-Lin Wu; Pei-Jung Chung; Nianhan Ma
Journal:  Biomolecules       Date:  2021-11-08

Review 4.  Revisiting miRNA Association with Melanoma Recurrence and Metastasis from a Machine Learning Point of View.

Authors:  Aigli Korfiati; Katerina Grafanaki; George C Kyriakopoulos; Ilias Skeparnias; Sophia Georgiou; George Sakellaropoulos; Constantinos Stathopoulos
Journal:  Int J Mol Sci       Date:  2022-01-24       Impact factor: 5.923

5.  Circ-FOXM1 contributes to cell proliferation, invasion, and glycolysis and represses apoptosis in melanoma by regulating miR-143-3p/FLOT2 axis.

Authors:  Shan Tian; Gangwen Han; Lulu Lu; Xiangyu Meng
Journal:  World J Surg Oncol       Date:  2020-03-17       Impact factor: 2.754

6.  A Potential Tumor Suppressor Gene Named miR-508-5p Inhibited the Proliferation and Invasion of Human Melanoma Cells by Targeting KIT.

Authors:  Lin Dang; Yan Wang; Cuiping Shi; Mengsi Liao; Zhaojun Sun; Sining Fang
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.